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Abstract	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  13	  
The	   influence	   of	   the	  microbial–mammalian	  metabolic	   axis	   is	   becoming	   increasingly	   important	   for	  14	  
human	   health.	   Bacterial	   fermentation	   of	   carbohydrates	   and	   proteins	   produces	   short-­‐chain	   fatty	  15	  
acids	   (SCFA)	   and	   a	   range	   of	   other	   metabolites	   including	   those	   from	   aromatic	   amino	   acid	   (AAA)	  16	  
fermentation.	  SCFA	  influence	  host	  health	  as	  energy	  sources	  and	  via	  multiple	  signalling	  mechanisms.	  17	  
Bacterial	   transformation	  of	   fibre-­‐related	  phytochemicals	   is	   associated	  with	  a	   reduced	   incidence	  of	  18	  
several	  chronic	  diseases.	  The	  ‘gut–liver	  axis’	  is	  an	  emerging	  area	  of	  study.	  Microbial	  deconjugation	  of	  19	  
xenobiotics	  and	  release	  of	  aromatic	  moieties	   into	  the	  colon	  can	  have	  a	  wide	  range	  of	  physiological	  20	  
consequences.	  In	  addition,	  the	  role	  of	  the	  gut	  microbiota	  in	  choline	  deficiency	  in	  non-­‐alcoholic	  fatty	  21	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Introduction	  37	  
The	  human	   large	   intestine	   is	   colonised	  by	  dense	  microbial	   communities	   that	  utilise	  both	  diet-­‐	  and	  38	  
host-­‐derived	   energy	   sources	   for	   growth,	   predominantly	   through	   fermentative	   metabolism.	   This	  39	  
highly	   diverse	   community	   has	   the	   capacity	   to	   perform	   an	   extraordinary	   range	   of	   biochemical	  40	  
transformations	  that	  go	  well	  beyond	  those	  encoded	  by	  the	  host	  genome,	  and	  these	  activities	  exert	  41	  
an	   important	   influence	   upon	   many	   aspects	   of	   human	   health.	   Metabolites	   formed	   by	   the	   gut	  42	  
microbiota	  are	  largely	  determined	  by	  the	  composition	  of	  the	  diet	  and	  the	  pattern	  of	  food	  intake,	  and	  43	  
it	   is	   now	   clear	   that	   the	   species	   composition	   of	   the	   colonic	  microbiota	   is	   itself	   altered	   by	   the	   diet	  44	  
[1*,2,	   3**].	   This	   review	  will	   consider	   selected	   examples	  where	   recent	   progress	   has	   been	  made	   in	  45	  
understanding	  the	  links	  between	  diet,	  gut	  microbial	  activity	  and	  metabolites	  relevant	  to	  health.	  46	  
	  47	  
Bacterial	   metabolites	   derived	   from	   the	   fermentation	   of	   plant-­‐derived	  48	  
carbohydrates	  and	  their	  impact	  on	  the	  host	  49	  
	  50	  
Many	  carbohydrates	  (CHOs)	  present	  in	  plant-­‐derived	  foods	  are	  digested	  slowly,	  if	  at	  all,	  in	  the	  small	  51	  
intestine,	  making	   them	  available	   for	  microbial	   fermentation	   in	   the	   large	   intestine.	   Intake	  of	   starch	  52	  
that	  is	  resistant	  to	  digestion	  in	  the	  small	  intestine	  (resistant	  starch)	  can	  have	  benefits	  for	  metabolic	  53	  
health	   [4]	   and	   results	   in	   changes	   in	   the	   gut	  microbiota	   [1*].	   Recent	  work	   also	   shows	   a	   beneficial	  54	  
influence	   of	   whole	   grain	   intake	   upon	   inflammation,	   again	   with	   concomitant	   changes	   in	   the	   gut	  55	  
microbiota	   [5*].	  Diet-­‐induced	   changes	   in	   the	  metabolic	   activity	   of	   the	   gut	  microbiota	   are	   thought	  56	  
likely	  to	  mediate	  these	  effects.	  57	  
	  58	  
Hexose	  and	  pentose	  sugars	  are	  fermented	  by	  isolated	  human	  colonic	  bacteria	  via	  pathways	  leading	  59	  
to	   the	   formation	   of	   acetate,	   succinate,	   propionate,	   butyrate,	   formate,	   lactate,	   ethanol,	   hydrogen	  60	  
and	   CO2,	   depending	   on	   the	   strain	   and	   species.	   Butyrate	   formation	   occurs	   in	   certain	   Firmicutes	  61	  
bacteria,	   either	   via	   butyrate	   kinase	   (in	   many	   Clostridium	   and	   Coprococcus	   species)	   or	   via	   butyryl	  62	  
CoA:acetate	   CoA	   transferase	   [6].	   The	   latter	   pathway	   is	   found	   in	   the	   numerically	   predominant	  63	  
butyrate-­‐producing	   species	   of	   Roseburia,	   Eubacterium	   rectale,	   E.	   hallii	   and	   Faecalibacterium	  64	  
prausnitzii,	   and	   involves	   the	   net	   uptake	   of	   external	   acetate	   [7].	   Acetate	   is	   produced	   by	   most	  65	  
anaerobes,	   including	   acetogens	   that	   are	   able	   to	   perform	   reductive	   acetogenesis	   from	   formate	   or	  66	  
hydrogen	   plus	   CO2.	   Producers	   of	   succinate	   and	   propionate	   largely	   belong	   to	   the	   phylum	  67	  
The	  full,	  proofread	  version	  of	  this	  review	  was	  published	  by	  Elsevier	  and	  can	  be	  found	  at	  
http://www.sciencedirect.com/science/article/pii/S1369527413000878	  
Bacteroidetes,	   but	   also	   include	   some	   Firmicutes.	   Lactate	   can	   be	   formed	   by	   many	   groups,	   but	   is	  68	  
generally	  converted	  into	  acetate,	  propionate	  or	  butyrate	  by	  a	  subset	  of	  lactate-­‐utilizing	  species	  [8].	  69	  
Formation	   of	   the	   gases	   hydrogen	   and	   CO2	  varies	   widely	   between	   species	   in	   pure	   culture;	   in	   the	  70	  
mixed	   community	   these	  products	  are	  partially	   converted	   to	  acetate,	  methane	  or	  hydrogen	   sulfide	  71	  
[9].	   The	   net	   outcome	   of	   all	   of	   these	   complex	   cross-­‐feeding	   interactions	   for	   a	   typical	   healthy	  72	  
microbiota	  is	  that,	  in	  faecal	  samples,	  acetate	  is	  the	  dominant	  short-­‐chain	  fatty	  acid	  (SCFA)	  detected	  73	  
(typically	   40	   –	   70	   mM)	   followed	   by	   propionate	   and	   butyrate	   (each	   10	   -­‐	   30	   mM)	   [10].	   While	  74	  
alternative	   products	   such	   as	   ethanol,	   succinate	   and	   lactate	   are	   normally	   found	   at	   lower	  75	  
concentrations,	  they	  can	  accumulate	  in	  some	  circumstances	  and	  a	  link	  has	  been	  proposed	  between	  76	  
endogenous	  alcohol	  formation	  and	  non-­‐alcoholic	  steatohepatitis	  [11].	  77	  
	  78	  
At	   these	   concentrations,	   SCFA	   have	   a	   major	   impact	   on	   the	   large	   intestinal	   environment	   and	   on	  79	  
absorption	  from	  the	  lumen.	  While	  butyrate	  is	  largely	  utilised	  by	  the	  gut	  epithelium,	  and	  propionate	  80	  
is	   largely	  metabolised	   in	   the	   liver,	   acetate	   is	   the	   SCFA	   that	   reaches	   the	   highest	   concentrations	   in	  81	  
plasma	   [10].	   There	   is	   increasing	   evidence	   that	   acetate	   plays	   an	   important	   role	   in	   controlling	  82	  
inflammation	   and	   in	   combating	   pathogen	   invasion	   [12,13].	   Acetate	   and	   lactate	   were	   also	   found	  83	  
recently	   to	   influence	   cyclin	   gene	   expression	   and	   epithelial	   cell	   proliferation	   in	   a	   pH-­‐dependent	  84	  
manner	   in	   vitro	   [14].	   The	   importance	  of	   butyrate	   as	   an	   energy	   source	   for	   epithelial	   cells	   has	   long	  85	  
been	  recognised,	  but	   its	  role	   in	  regulating	   inflammation,	  cellular	  differentiation	  and	  apoptosis,	  and	  86	  
in	   helping	   to	   prevent	   colorectal	   cancer,	   is	   still	   emerging	   [15].	   Interestingly,	   butyrate	  was	   recently	  87	  
found	   to	  be	   the	  most	  potent	   SCFA	   in	   activating	   the	  AP-­‐1	   signalling	  pathway	   in	   epithelial	   cell	   lines	  88	  
[16].	  Interactions	  have	  been	  recognised	  between	  SCFA	  and	  the	  host	  cell	  receptors	  FFAR2	  and	  FFAR3	  89	  
that	   might	   influence	   satiety,	   protect	   against	   diet-­‐induced	   obesity	   and	   improve	   insulin	   sensitivity,	  90	  
with	   propionate	   considered	   to	   have	   a	   potentially	   important	   role	   	   [17,18].	   In	   view	   of	   this	   it	   is	  91	  
important	   to	   understand	   how	   diet	   and	   microbiota	   composition	   can	   influence	   relative,	   as	   well	   as	  92	  
total,	   SCFA	   production.	   Studies	   in	   obese	   subjects	   on	   weight	   loss	   diets	   demonstrate	   that	   dietary	  93	  
intake	   of	   CHO	   has	   a	  major	   impact	   on	   faecal	   SCFA	   concentrations	   [19,20**]	   presumably	   reflecting	  94	  
decreased	   fermentation	   in	   the	   colon	   (Fig.	   1).	  More	   surprising,	   however,	   is	   that	   butyrate	   per	   cent	  95	  
responded	  disproportionately,	  an	  effect	  that	  correlates	  with	  a	  marked	  decrease	  in	  the	  Roseburia-­‐E.	  96	  
rectale	  group	  of	  butyrate-­‐producing	  bacteria	  [19].	  This	  may	  be	  explained	  by	  the	  greater	  dependence	  97	  
of	  this	  group,	  compared	  with	  other	  members	  of	  the	  microbiota,	  on	  intake	  of	  resistant	  dietary	  CHOs,	  98	  
and	  provides	   evidence	   that	   SCFA	   relative	  production	   rates	   are	   responsive	   to	  diet	   composition.	  An	  99	  
inverse	  relationship	  has	  been	  noted	  between	  faecal	  pH	  and	  butyrate	  concentration	  in	  vivo	  [21];	  this	  100	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is	  likely	  to	  reflect	  the	  great	  competitive	  ability	  of	  some	  butyrate-­‐producers	  at	  the	  reduced	  pH	  arising	  101	  
from	  active	  fermentation	  in	  the	  proximal	  colon	  [22].	  102	  
Decreased	   numbers	   of	   butyrate-­‐producing	   bacteria,	   especially	   Faecalibacterium	   prausnitzii,	   have	  103	  
been	  noted	  in	  patients	  suffering	  from	  Crohn’s	  disease.	  This	  species	  exerts	  anti-­‐inflammatory	  effects	  104	  
that	   appear	   to	   involve	   soluble	   factors	   in	   addition	   to	  butyrate	   [23].	   Interestingly,	  F.	   prausnitzii	  was	  105	  
recently	   shown	   to	   diminish	   the	   impact	   of	   the	   acetate-­‐producing	   species	   B	   .	   thetaiotaomicron	   on	  106	  
mucus	  production	  and	  goblet	  cell	  development	  in	  a	  gnotobiotic	  rodent	  model	  [24].	  107	  
	  108	  
Formation	  and	  metabolism	  of	  aromatic	  compounds	  109	  
	  110	  
Fibre-­‐related	  phytochemicals	  111	  
It	  is	  suggested	  that	  the	  inverse	  relationship	  between	  the	  intake	  of	  fibre-­‐rich	  diets	  and	  the	  incidence	  112	  
of	   several	   chronic	   diseases	   is	   mediated	   in	   part	   by	   the	   gut	   microbiota.	   Microbial	   release	   of	  113	  
phytochemical	   metabolites	   may	   be	   a	   contributing	   factor	   and	   most	   widely	   studied	   for	   disease	  114	  
prevention	   are	   the	   aromatic	   metabolites	   produced	   by	   the	   phenylpropanoid	   pathway	   [25,26].	  115	  
Increasing	  the	  fibre	  content	  of	  the	  diet	  from	  8.8	  to	  14	  g	  day-­‐1	  in	  a	  human	  volunteer	  study	  resulted	  in	  116	  
significantly	  increasing	  certain	  phenolic	  acids	  and	  their	  derivatives	  in	  the	  gut,	  specifically	  ferulic	  acid,	  117	  
4-­‐hydroxy-­‐3-­‐methoxyphenylpropionic	   acid	   and	   3-­‐hydroxyphenylpropionic	   acid	   [20].	   Ferulic	   acid,	  118	  
which	  is	  found	  extensively	  bound	  to	  plant	  polysaccharides,	  can	  be	  released	  and	  metabolised	  by	  the	  119	  
gut	  microbiota	  [20,27]	  (Fig.	  2).	  Indeed,	  the	  major	  esters	  of	  other	  phenolic	  acids	  such	  as	  caffeic	  acid	  120	  
(chlorogenic	   and	   caftaric	   acid)	   are	   also	   rapidly	   de-­‐esterified	   by	   human	   faecal	   microbiota	   [28].	   It	  121	  
appears	   that	   the	   gut	  microbiota	   can	   effectively	   de-­‐esterify	   compounds,	   whether	   the	   conjugate	   is	  122	  
quinic	   acid,	   tartaric	   acid	   or	   a	   sugar	   moiety	   to	   release	   the	   aglycone	   for	   further	   metabolism.	   Gut	  123	  
bacteria	   can	   also	   effectively	   hydrogenate	   the	   α,β-­‐unsaturated	   bond	   present	   on	   the	   side	   chain	   of	  124	  
phenolic	   acids	   [27]	   and	   the	   extent	   to	   which	   this	   occurs	   appears	   to	   be	   dependent	   on	   additional	  125	  
dietary	   factors,	   with	   high-­‐protein	   diets	   decreasing	   the	   efficiency	   of	   this	   transformation	   [20].	   Site-­‐126	  
specific	  dehydroxylation	  and	  demethylation	  of	   the	  phenolic	  hydroxyl	  present	   in	  phenolic	  acids	  has	  127	  
also	   been	   observed	   [20,	   27].	   The	   resultant	   microbial	   products	   of	   ferulic	   acid	   metabolism	   had	  128	  
differing	   effects	   on	  prostanoid	  production	   in	   vitro	   suggesting	   that	   the	  microbial	   transformation	  of	  129	  
dietary	  compounds	  will	  have	  important	  consequences	  for	  inflammation	  [27,29].	  130	  
 131	  
Aromatic	  amino	  acid	  metabolites	  132	  
Protein	  metabolism	  is	  a	  major	  alternative	  mechanism	  for	  production	  of	  aromatic	  metabolites	  [30]	  as	  133	  
observed	   in	   recent	   human	   dietary	   interventions	   involving	   carefully	   controlled	   intakes	   of	   CHO	   and	  134	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  full,	  proofread	  version	  of	  this	  review	  was	  published	  by	  Elsevier	  and	  can	  be	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  at	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protein	  [20].	  Until	  recently,	  the	  major	  metabolites	  of	  aromatic	  amino	  acid	  (AAA)	  fermentation	  were	  135	  
considered	   to	   be	   phenol,	   p-­‐cresol	   and	   indole,	   with	   p-­‐cresol	   suggested	   to	   be	   a	   product	   of	   phenol	  136	  
catabolism.	   It	   has	   now	   been	   demonstrated	   that	   a	  much	  wider	  metabolic	   pathway	   of	  metabolism	  137	  
exists	  for	  all	  three	  AAAs	  [31].	  In	  particular,	  phenylacetic	  acid,	  4-­‐hydroxyphenylacetic	  acid	  and	  indole-­‐138	  
3-­‐acetic	  acid	  were	  found	  to	  be	  major	  (de-­‐aminated	  and	  chain-­‐shortened)	  products	  of	  phenylalanine,	  139	  
tyrosine	   and	   tryptophan,	   respectively	   [31].	   Bacteria	   capable	   of	   producing	   these	   products	   could	  140	  
effectively	   metabolise	   all	   three	   AAA	   substrates.	   These	   included	   Bacteroides	   thetaiotaomicron,	   B.	  141	  
eggerthii,	   B.	   ovatus,	   B.	   fragilis,	   Parabacteroides	   distasonis	   and	   the	   Gram-­‐positive	   bacteria	  142	  
Clostridium	   bartlettii	   and	   Eubacterium	   hallii.	   Bacterial	   species	   that	   did	   not	   substantially	   produce	  143	  
these	   de-­‐aminated	   and	   chain-­‐shortened	   products	   were	   identified.	   These	   included	   Megamonas	  144	  
hypermegale,	   Roseburia	   intestinalis,	   Ruminococcus	   obeum,	   Eubacterium	   rectale	   and	  145	  
Faecalibacterium	  prausnitzii,	  but	  strains	  of	  these	  species	  often	  produced	  	  higher	  amounts	  of	  benzoic	  146	  
acid,	   4-­‐hydroxybenzoic	   acid	   and	   indole-­‐3-­‐carboxylic	   acid	   and	   oxidation	   products	   including	  147	  
phenylpyruvic	  acid,	  phenyllactic	  acid,	  4-­‐hydroxyphenyllactic	  acid,	  indole-­‐3-­‐pyruvic	  acid	  and	  indole-­‐3-­‐148	  
lactic	   acid.	   Given	   that	   certain	   species	   of	   gut	   bacteria	   can	   metabolise	   all	   three	   AAAs	   by	   specific	  149	  
mechanisms,	   it	   is	   likely	   that	   other	   structural	   forms	   of	   amino	   acids	   can	   undergo	   these	   molecular	  150	  
transformations.	  This	  will	  give	  rise	  to	  a	  range	  of	  novel	  metabolites,	  which	  require	  to	  be	  investigated	  151	  
to	  assess	  their	  potential	  to	  affect	  human	  health.	  152	  
	  153	  
It	  is	  clear	  that	  macronutrient	  balance	  influences	  not	  only	  the	  composition	  of	  the	  gut	  microbiota	  but	  154	  
also	   the	   availability	   of	   aromatic	   metabolites.	   Certain	   metabolites	   such	   as	   SCFA	   and	   phenyl	  155	  
metabolites	  can	  be	  produced	  by	  bacterial	  metabolism	  of	  both	  CHO	  and	  protein	  in	  the	  large	  intestine,	  156	  
whereas	   certain	  branched-­‐chain	   fatty	  acids	  and	  nitrogen-­‐containing	  metabolites	  are	   considered	   to	  157	  
be	  derived	  from	  protein	  metabolism	  alone.	  	  There	  is	  a	  positive	  association	  between	  animal	  protein	  158	  
consumption	   (specifically	   red	   and	   processed	   meat)	   and	   colorectal	   cancer	   [32].	   Evidence	   is	   also	  159	  
beginning	  to	  emerge	  that	  the	  concentrations	  of	  aromatic	  gut	  metabolites	  in	  the	  systemic	  circulation	  160	  
plays	  a	  role	  in	  vascular	  health	  and	  [33].  161	  
 162	  
Enterohepatic	  circulation	  and	  β -­‐glucuronidase	  163	  
Many	   diet-­‐derived	   aromatic	   compounds,	   including	   drugs,	   are	   treated	   as	   xenobiotics	   and	   are	  164	  
conjugated	   in	   the	   liver	   followed	   by	   release	   into	   the	   intestine	   via	   the	   bile.	   One	   of	   the	   main	  165	  
mechanisms	  for	  conjugation	  is	  glucuronidation,	  but	  it	  has	  been	  known	  for	  some	  time	  that	  bacterial	  166	  
β-­‐glucuronidases	  in	  the	  large	  intestine	  tend	  to	  cleave	  these	  conjugates,	  thus	  releasing	  the	  aromatic	  167	  
moiety	   and	   making	   it	   available	   again	   for	   re-­‐absorption.	   The	   gus	   gene	   from	   Escherichia	   coli	   was	  168	  
originally	  identified	  as	  encoding	  this	  activity.	  A	  recent	  survey	  used	  degenerate	  gus	  primers	  to	  detect	  169	  
The	  full,	  proofread	  version	  of	  this	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  by	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  and	  can	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related	  genes	  among	  the	  faecal	  microbiota	  from	  10	  healthy	  volunteers;	  this	  showed	  a	  highly	  uneven	  170	  
distribution	  with	  60	  %	  of	  sequences	  accounted	   for	  by	  only	  4	  operational	   taxonomic	  units,	  while	   in	  171	  
total	   96	  %	  of	   sequences	   came	   from	   Firmicutes	   and	   3	  %	   from	  E.	   coli	   [34].	   It	   seems	   likely	   that	   this	  172	  
activity	  is	  associated	  with	  enzymes	  involved	  in	  degrading	  plant	  polysaccharides.	  The	  contribution	  of	  173	  
a	   second	   putative	   β-­‐glucuronidase	   gene	   identified	   from	  metagenomic	   libraries	   [35]	   has	   still	   to	   be	  174	  
fully	  established	  [34].	  175	  
 176	  
The	   ‘gut–liver’	   axis,	   dietary	   amines,	   the	   intestinal	   microbiota	   and	   the	  177	  
methylamines’	  pathway	  178	  
The	  ‘gut–liver’	  axis	  179	  
Given	  the	  exposure	  of	  the	  liver	  to	  intestinal-­‐derived	  catabolites	  and	  the	  microbiota	  to	  biliary/waste	  180	  
products,	  the	  ‘gut–liver	  axis’	  is	  receiving	  great	  attention	  with	  respect	  to	  host	  health	  and	  its	  potential	  181	  
to	   affect	   systemic	   host	   processes	   [36].	   A	   recent	   study	   has	   nicely	   demonstrated	   the	   direct	  182	  
involvement	  of	   the	   gut	  microbiota	   in	   the	  development	  of	   obesity-­‐independent	  non-­‐alcoholic	   fatty	  183	  
liver	  disease	  (NAFLD),	  and	  the	  microbiota’s	   influence	  on	  whole	  body	  glucose	  homeostasis	  and	  liver	  184	  
lipid	  metabolism	   [37**].	  Germ-­‐free	  mice	   inoculated	  with	   intestinal	  microbiota	   from	   a	  mouse	   that	  185	  
developed	  hyperglycaemia	  and	  had	  a	  high	  plasma	  concentration	  of	  pro-­‐inflammatory	  cytokines	  after	  186	  
being	   fed	   a	   high-­‐fat	   diet	   developed	  hepatic	  macrovesicular	   steatosis	   (HMS)	   after	   high-­‐fat	   feeding,	  187	  
with	  increased	  expression	  of	  hepatic	  genes	  involved	  in	  de-­‐novo	  lipogenesis	  and	  lipid	  uptake	  (SREBP,	  188	  
ChREBP,	   acetyl-­‐CoA	   carboxylase	   1	   and	  CD36)	   observed.	   In	   comparison,	   germ-­‐free	  mice	   inoculated	  189	  
with	  faeces	  from	  a	  mouse	  that	  was	  normoglycaemic	  and	  had	  a	  lower	  level	  of	  systemic	  inflammation	  190	  
after	   being	   fed	   a	   high-­‐fat	   diet	   developed	   low-­‐level	   steatosis	   on	   the	   same	   diet	   [37**].	   Differences	  191	  
were	  observed	  in	  the	  faecal	  microbiota	  of	  the	  two	  groups	  of	  mice:	  Lachnospiraceae	  and	  Barnesiella	  192	  
(Porphyromonadaceae)	   sequences	  were	   significantly	   overrepresented	   in	   the	   HMS	  mice,	   while	   the	  193	  
low-­‐level	   steatosis	   mice	   had	   an	   increased	   number	   of	   sequences	   related	   to	   Bacteroides	   vulgatus.	  194	  
Concentrations	   of	   isobutyrate	   and	   isovalerate,	   branched-­‐chain	   amino	   acids	   resulting	   from	   the	  195	  
bacterial	  fermentation	  of	  valine	  and	  leucine,	  respectively,	  were	  significantly	  higher	  in	  the	  caecum	  of	  196	  
the	   HMS	   mice.	   In	   addition,	   these	   animals	   had	   significantly	   higher	   fasting	   glycaemia,	   fasting	  197	  
insulinaemia,	  homeostasis	  model	  assessment—insulin	  resistance	  index	  and	  leptinaemia,	  and	  higher	  198	  
plasma	   concentrations	   of	   aspartate	   aminotransferase	   than	   the	   animals	   that	   developed	   low-­‐level	  199	  
steatosis.	   Taken	   together,	   these	   results	   demonstrate	   that	   the	   gut	   microbiota	   constitutes	   an	  200	  
environmental	  factor	  driving	  the	  progression	  of	  NAFLD	  [37**].	  201	  
	  202	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Although	  both	  groups	  of	  animals	  were	  fed	  the	  same	  diet	  in	  the	  Le	  Roy	  study	  [37**],	  it	  is	  well	  known	  203	  
that	  the	  intestinal	  microbiota	  can	  influence	  the	  ‘gut–liver	  axis’	  and	  the	  development	  of	  NAFLD	  (and	  204	  
other	  diseases)	  by	  microbial	  utilization	  of	  dietary	  methylamines.	  205	  
	  206	  
Choline	  deficiency	  and	  NAFLD	  207	  
Choline	  is	  an	  essential	  nutrient	  of	  the	  vitamin	  B	  complex	  with	  numerous	  roles	  in	  the	  body:	  acting	  as	  208	  
a	   methyl	   donor	   in	   biochemical	   reactions,	   as	   a	   precursor	   for	   the	   biosynthesis	   of	   phospholipids	  209	  
[phosphatidylcholine	   (PC),	   lysophosphatidylcholine,	   choline	   plasmalogen	   and	   sphingomyelin],	   of	  210	  
acetylcholine	   and	   of	   lipoproteins,	   and	   in	   homocysteine	   reduction	   [38,39,40].	   The	   main	   fate	   of	  211	  
choline	  in	  the	  body	  is	  its	  incorporation	  into	  PC	  via	  the	  Kennedy	  pathway	  [41].	  212	  
	  213	  
Exogenous	   choline	   is	   derived	   from	   either	   dietary	   choline	   or,	  more	   commonly,	   PC	   from	   plant	   and	  214	  
animal	  material	   [38,39,42].	   Foods	  high	   in	   choline	   include	  meat	  and	  dairy	  products,	   fish,	   soybeans,	  215	  
nuts	   and	   whole	   grains,	   with	   PC	   added	   to	   a	   number	   of	   foods	   as	   an	   emulsifier	   [43].	   Endogenous	  216	  
sources	  of	  choline,	   in	   the	   form	  of	  PC,	   include	  biliary	   lipids,	  exfoliated	  epithelial	   cells	  and	   intestinal	  217	  
bacteria	   [44,45].	   De	   novo	   synthesis	   of	   choline	   occurs	   via	   a	   reaction	   catalysed	   by	  218	  
phosphatidylethanolamine-­‐N-­‐methyltransferase	  (PEMT)	  [41].	  219	  
	  220	  
The	   intestinal	   microbiota	   plays	   a	   role	   in	   the	   catabolism	   of	   choline	   in	   humans	   and	   rodents	  221	  
[46,47,48,49,],	  with	  trimethylamine	  (TMA),	  acetate	  and	  ethanol	   the	  products	  of	   fermentation	  [50].	  222	  
Choline	  degradation	  by	  the	  human	  intestinal	  microbiota	  is	  temporally	  stable	  [47].	  TMA	  produced	  by	  223	  
intestinal	   bacteria	   from	   choline	   is	   absorbed	   by	   colonic	   cells	   and	   converted	   to	   trimethylamine-­‐N-­‐224	  
oxide	   (TMAO)	   by	   flavin	   mono-­‐oxygenase	   enzymes	   [51],	   demethylated	   into	   dimethylamine	   and	  225	  
(mono)methylamine	   in	   the	   liver,	   or	   excreted	   in	   the	   urine.	   The	  methylamine	   pathway	   is	   a	   typical	  226	  
example	  of	  microbial–mammalian	  co-­‐metabolism	  [52,53]	  (Figure	  3).	  227	  
	  228	  
Knowledge	  pertaining	  to	  those	  members	  of	  the	  intestinal	  microbiota	  responsible	  for	  producing	  TMA	  229	  
from	   choline	   is	   sparse.	   In	   silico	   predictions	   have	   suggested	   that	   several	   members	   of	   the	   human	  230	  
intestinal	  microbiota	  (including	  Clostridium,	  Anaerococcus,	  Collinsella,	  Desulfitobacterium,	  Klebsiella,	  231	  
Escherichia,	  Providencia,	  Yokenella	  and	  Proteus	  spp.)	  have	  the	  ability	  to	  degrade	  choline	  to	  TMA	  via	  232	  
choline	  TMA-­‐lyase	   [54**].	   In	  addition	   to	   the	  aforementioned	  species,	  many	  more	  members	  of	   the	  233	  
human	   intestinal	  microbiota	  may	   be	   able	   to	   degrade	   choline	   to	   TMA	   using	   the	   same	  mechanism	  234	  
and/or	  via	  an	  alternative	  pathway(s).	  235	  
	  236	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  237	  
Choline-­‐deficient	   diets	   in	   humans	   (≤50	  mg	   day-­‐1)	   and	   rodents	   are	   known	   to	   lead	   to	   NAFLD,	   non-­‐238	  
alcoholic	   steatohepatitis	   (NASH)	   and	   hepatic	   damage	   [39,55].	   To	   combat	   these	   and	   other	  239	  
complications	  (e.g.	  infertility,	  renal	  haemorrhage	  and	  hypertension),	  the	  Food	  and	  Nutrition	  Board	  of	  240	  
the	  Institute	  of	  Medicine	  of	  America	  recommends	  an	  adequate	  intake	  of	  choline	  for	  men	  is	  550	  mg	  241	  
per	   day	   and	   for	   women	   425	   mg	   per	   day	   [38,43].	   Reduced	   or	   delayed	   urinary	   excretion	   of	  242	  
TMAO/TMA	   is	   specific	   to	   hepatic	   disease,	   and	   it	   has	   been	   suggested	   dysbiosis	   of	   the	   intestinal	  243	  
microbiota	  in	  patients	  with	  hepatobiliary	  diseases	  may	  delay/decrease	  conversion	  of	  choline	  to	  TMA	  244	  
and	  subsequent	  urinary	  excretion	  of	  TMAO/TMA	  [47,48].	  Analyses	  of	  urinary	  metabolites	  produced	  245	  
by	  mice	   fed	  high-­‐fat	   diets	   led	   to	   the	  proposals	   that	  microbial	   utilization,	   and	   subsequent	   reduced	  246	  
availability,	  of	  dietary	  choline	  contributes	  to	  the	  development	  of	  NAFLD	  [56]	  and	  insulin	  resistance	  247	  
[57].	   The	   only	   study	   to	   date	   comparing	   the	   faecal	   microbiotas	   of	   healthy	   and	   NAFLD	   individuals	  248	  
found	   no	   difference	   in	   their	   compositions	   [58].	   However,	   studies	   in	   rodents	   have	   shown	   that	  249	  
probiotic	  [59]	  and	  antibiotic	  administration	  [60**]	  can	  offer	  protection	  against	  the	  onset	  of	  NAFLD.	  250	  
The	  role	  for	  dietary	  choline	  in	  NAFLD	  can	  be	  explained	  by	  the	  bioavailability	  of	  free	  choline	  to	  form	  251	  
lipoproteins	   in	   the	   liver	   (in	   particular,	   VLDL),	  which	   allows	   the	   export	   of	   free	   fatty	   acids	   from	   this	  252	  
organ.	  If	  the	  gut	  microbiome	  converts	  excessive	  amounts	  of	  dietary	  choline	  into	  TMA,	  this	  leads	  to	  253	  
reduced	  choline	  bioavailability	  and,	  therefore,	  NAFLD	  [57].	  254	  
	  255	  
Recent	  work	  has	  demonstrated	   that	   changes	   in	   choline	   levels	   in	  a	   standardized	  diet	  modulate	   the	  256	  
faecal	  microbiota	  and	  can	   lead	  to	  the	  development	  of	   fatty	   liver	   in	  human	  subjects	   [61**].	  Fifteen	  257	  
females	   (BMI	   15–34)	   on	   a	   2-­‐week	   in-­‐patient	   study	  were	   fed	   a	   standardized	   diet	   in	  which	   choline	  258	  
levels	  were	  manipulated.	  Gammaproteobacteria	  were	  seemingly	   inhibited	  by	  high	   levels	  of	  dietary	  259	  
choline,	   and	   negatively	   correlated	   with	   the	   per	   cent	   change	   in	   liver	   fat/spleen	   fat	   ratios.	  260	  
Erysipelotrichi	   sequence	   numbers	   were	   positively	   correlated	   with	   the	   per	   cent	   change	   in	   liver	  261	  
fat/spleen	   fat	   ratios.	   This	   led	   to	   the	   suggestion	   that	   baseline	   levels	   of	   these	   taxa	  may	  predict	   the	  262	  
susceptibility	  of	  an	   individual	   to	   fatty	   liver	  disease	   from	  a	  choline-­‐deficient	  diet	   [61**].	  Combining	  263	  
PEMT	  promoter	  SNP	  rs12325817	  phenotype,	  Gammaproteobacteria	  and	  Erysipelotrichi	  data	  proved	  264	  
a	   powerful	   method	   for	   predicting	   the	   physiological	   effects	   of	   choline	   deficiency,	   and	   led	   the	  265	  
researchers	  to	  hypothesize	  that	  those	  with	  the	  wild-­‐type	  version	  SNP	  in	  the	  PEMT	  gene	  were	  better	  266	  
able	   to	   produce	   PC	   endogenously	   and	   were	   less	   affected	   by	   the	   composition	   of	   their	   intestinal	  267	  
microbiota	  in	  relation	  to	  the	  effects	  of	  choline	  deficiency.	  268	  
	  269	  
The	  full,	  proofread	  version	  of	  this	  review	  was	  published	  by	  Elsevier	  and	  can	  be	  found	  at	  
http://www.sciencedirect.com/science/article/pii/S1369527413000878	  
Interactions	   between	   the	   intestinal	   microbiota,	   inflammasomes	   and	   NAFLD	   are	   known	   to	   occur.	  270	  
Deficiencies	  of	  the	  NLRP3	  and	  NLRP6	  inflammasomes	  positively	  regulated	  NAFLD	  progression	  in	  mice	  271	  
harbouring	   a	   colitogenic	   intestinal	  microbiota	   [60**].	   Switching	   the	   animals	   to	   a	   choline-­‐deficient	  272	  
diet	   modulated	   the	   faecal	   microbiota,	   particularly	   representation	   of	   members	   of	   the	   families	  273	  
Porphyromondaceae,	   Erysipelotrichaceae	   and	   Prevotellaceae.	   Modulation	   of	   the	   intestinal	  274	  
microbiota	  by	  the	  choline-­‐deficient	  diet	  was	  thought	  to	  promote	  a	  TLR4/TLR9	  signalling	  cascade	   in	  275	  
the	  liver	  that	   led	  to	  enhanced	  hepatic	  tumour	  necrosis	  factor	  expression	  that	  drove	  progression	  to	  276	  
NASH	  in	  susceptible	  animals.	  277	  
	  278	  
Microbial	   metabolism	   of	   phosphatidylcholine	   and	   L-­‐carnitine	   is	   associated	   with	   cardiovascular	  279	  
disease	  280	  
Choline	  present	  in	  dietary	  PC	  is	  degraded	  by	  intestinal	  bacteria,	  but	  is	  more	  resistant	  to	  degradation	  281	  
than	  free	  choline	  [49,62].	  The	  intestinal	  microbiota	  of	  mice	  is	  able	  to	  catabolise	  choline	  from	  dietary	  282	  
PC	  via	  an	  unknown	  mechanism,	  which	  led	  to	  the	  proposal	  of	  a	  linear	  pathway	  PC	  →	  choline	  →	  TMA	  283	  
→	  TMAO	  [63*].	  It	  is	  known	  that	  human	  intestinal	  bacteria	  (bacteroides,	  bifidobacteria	  and	  clostridia)	  284	  
are	  able	  to	  degrade	  PC	  with	  the	  release	  of	  choline	  [62].	  285	  
	  286	  
	  287	  
Following	  the	  association	  of	  methylamines	  with	  murine	  insulin-­‐resistance	  phenotypes	  [57],	  Wang	  et	  288	  
al.	  [63*]	  proposed	  a	  link	  between	  degradation	  of	  dietary	  PC,	  the	  intestinal	  microbiota	  and	  TMAO	  in	  289	  
cardiovascular	  disease.	  This	  hypothesis	  was	  tested	  further	  in	  a	  study	  in	  which	  humans	  were	  given	  a	  290	  
PC	  challenge	  and	  their	  plasma	  levels	  of	  TMAO	  were	  measured	  before	  and	  after	  suppression	  of	  the	  291	  
intestinal	  microbiota	  with	  antibiotics	  [64**].	  Time-­‐dependent	  increases	  in	  plasma	  TMAO	  levels	  were	  292	  
observed	   at	   the	   first	   challenge,	  with	   TMAO	  production	   suppressed	   after	   antibiotic	   administration.	  293	  
Removal	   of	   antibiotics,	   and	   ‘release’	   of	   the	   microbiota,	   reinstated	   TMAO	   plasma	   levels	   post-­‐PC	  294	  
challenge,	  demonstrating	  the	  role	  of	  the	  microbiota	  in	  increasing	  circulating	  levels	  of	  TMAO	  derived	  295	  
from	  PC.	  The	  authors	  also	  examined	  the	  relationship	  between	  fasting	  TMAO	  levels	  in	  4007	  patients	  296	  
undergoing	   elective	   coronary	   angiography	   and	   the	   occurrence	   of	   major	   cardiovascular	   events	  297	  
(death,	  heart	  attack	  or	  stroke)	  over	  a	  three-­‐year	  follow-­‐up	  period.	  An	  increased	  fasting	  plasma	  level	  298	  
of	  TMAO	  was	  associated	  with	  experiencing	  a	  major	  cardiovascular	  event	  [64**].	  299	  
	  300	  
The	   relationship	   between	   TMAO	  produced	   from	  dietary	  methylamines	   and	   cardiovascular	   disease	  301	  
has	   recently	   been	   extended	   to	   include	   L-­‐carnitine,	   a	   compound	   abundant	   in	   red	   meat	   [65**].	  302	  
Antibiotic-­‐induced	   suppression	   of	   the	   microbiota	   of	   humans	   led	   to	   almost-­‐complete	   absence	   of	  303	  
The	  full,	  proofread	  version	  of	  this	  review	  was	  published	  by	  Elsevier	  and	  can	  be	  found	  at	  
http://www.sciencedirect.com/science/article/pii/S1369527413000878	  
TMAO	  from	  plasma	  and	  urine	  after	  L-­‐carnitine	  challenge.	  In	  addition,	  it	  was	  shown	  that	  omnivorous	  304	  
humans	  have	  far	  higher	  circulating	  levels	  of	  TMAO	  in	  their	  plasma	  than	  their	  vegan	  and	  vegetarian	  305	  
counterparts	   after	   L-­‐carnitine	   supplementation,	   with	   negligible	   TMAO	   formation	   in	   vegans	   post-­‐306	  
carnitine	   challenge.	  Vegetarians	  and	  vegans	  have	  higher	  plasma	   levels	  of	   carnitine	   compared	  with	  307	  
their	  omnivorous	  counterparts,	  though	  it	  is	  not	  known	  if	  this	  is	  due	  to	  reduced	  microbial	  metabolism	  308	  
of	  carnitine	  to	  TMA	  by	  the	  intestinal	  microbiota	  of	  the	  non-­‐omnivores.	  This	  suggests	  that	  the	  human	  309	  
intestinal	  microbiota	  can	  be	  modulated	  by	  dietary	  means	  with	   respect	   to	  how	   it	  processes	  dietary	  310	  
methylamines.	  311	  
	  312	  
High	   levels	   of	   plasma	   carnitine	   were	   associated	   with	   cardiovascular	   disease	   but	   only	   in	   those	  313	  
patients	  with	   accompanying	   high	   levels	   of	   plasma	   TMAO	   in	   a	   cohort	   of	   2595	   patients	   undergoing	  314	  
cardiac	   evaluation	   [64**].	   Using	   an	   Apoe-­‐/-­‐	   mouse	   model,	   Koeth	   et	   al.	   [65**]	   demonstrated	   that	  315	  
atherosclerosis	   plaque	   formation	   during	   carnitine	   supplementation	   was	   microbiota-­‐dependent,	  316	  
being	   directly	   related	   to	   the	   presence	   of	   bacterially-­‐derived	   TMAO/TMA	   in	   plasma.	   TMAO	   is	  317	  
currently	  thought	  to	  induce	  atherosclerosis	  by	  promoting	  macrophage	  cholesterol	  accumulation	  by	  318	  
increasing	   cell	   surface	   expression	   of	   CD36	   and	   scavenger	   receptor	   A,	   pro-­‐atherogenic	   scavenger	  319	  
receptors	   [63*,65**],	   and	   by	   repressing	   reverse	   cholesterol	   transport	   and	   several	   bile	   acid	  320	  
transporters	  in	  the	  liver	  [65**].	  321	  
	  322	  
Conclusion	  323	  
Microbial–mammalian	   co-­‐metabolism	   is	   shaping	   human	   health	   in	   many	   ways.	   In	   this	   review,	   we	  324	  
have	  covered	   recent	   findings	  on	  SCFA,	  AAA	  and	  methylamine	  metabolism	  and	   their	   consequences	  325	  
on	  human	  health	  and	  disease,	  which	  are	  illustrating	  particularly	  well	  this	  metabolic	  symbiosis.	  With	  326	  
the	  constant	  refinement	  of	  metagenomics	  and	  metabolomics,	  further	  insights	  will	  become	  available	  327	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Figure	   1.	   Impact	   of	   reduced	   CHO	  weight	   loss	   (WL)	   diets	   in	  male	   obese	   volunteers	   on	   fecal	   SCFA	  550	  
concentrations.	   Data	   are	   from	   two	   separate	   dietary	   cross-­‐over	   studies	   that	   are	   reported	   in	   [19]	  551	  
(study	   1)	   and	   [20**]	   (study	   2):	   M	   –	   weight	   maintenance	   diet	   (360-­‐400	   g	   day-­‐1	   CHO,	   22-­‐28	   NSP),	  552	  
HPMC	   –	   high	   protein,	   moderate	   CHO	   WL	   diet	   (164-­‐182	   g	   day-­‐1	   CHO,	   12-­‐13	   NSP	   ),	   HPLC	   –	   high	  553	  
protein,	  low	  CHO	  WL	  diet	  (23-­‐24	  g	  day-­‐1	  CHO,	  6-­‐9	  NSP).	  In	  addition	  to	  the	  evident	  decrease	  in	  total	  554	  
SCFA,	  both	  studies	  detected	  a	  significant	  decrease	  in	  per	  cent	  butyrate	  among	  SCFA,	  while	  in	  study	  2	  555	  
the	  per	   cent	  of	  minor	  SCFA	   (valerate,	   isobutyrate,	   isovalerate)	   that	  were	  derived	   from	  amino	  acid	  556	  
fermentation	  increased,	  reflecting	  the	  higher	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  intake	  on	  the	  WL	  diets.	  557	  
	  558	  
Figure	   2.	   Concentration	  of	   fibre-­‐derived	   ferulic	   acid	   and	   its	  major	  metabolites	  measured	   in	   faecal	  559	  
samples	   following	   high	   protein	   dietary	   interventions.	   Metabolite	   1	   =	   4-­‐hydroxy-­‐3-­‐560	  
methoxyphenylpropionic	  acid,	  Metabolite	  2	  =	  3,4-­‐dihydroxyphenylpropionic	  acid,	  Metabolite	  3	  =	  3-­‐561	  
hydroxyphenylpropionic	  acid.	  M	  =	  maintenance	  diet	  (fibre	  content	  22	  g	  day-­‐1),	  HPMC	  =	  high	  protein	  562	  
moderate	  CHO	  diet	  (fibre	  content	  14	  g	  day-­‐1)	  and	  HPLC	  =	  high	  protein	  low	  CHO	  diet	  (fibre	  content	  8.8	  563	  
g	   day-­‐1).	   Ferulic	   acid	   =	   4-­‐hydroxy-­‐3-­‐methoxycinnamic	   acid.	   Data	   are	   given	   as	   mean	   ±	   standard	  564	  
deviation	  (n	  =	  8	  volunteers).	  Statistical	  data	  were	  calculated	  as	  a	  one-­‐way	  ANOVA	  to	  compare	  diet	  565	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diets.	  Adapted	  from	  [20**].	  567	  
	  568	  
Figure	  3.	  The	  methylamines’	  pathway	  and	  the	  microbial–mammalian	  metabolic	  axis.	  TMA	  is	  derived	  569	  
from	  microbial	  degradation	  of	  choline,	  a	  dietary	  component	  that	  can	  also	  be	  obtained	  by	  cleavage	  of	  570	  
dietary	  PC,	  and	  of	  L-­‐carnitine.	  TMA	  is	  absorbed	  by	  the	  host	  to	  be	  N-­‐oxidised	  into	  TMAO	  by	  FMO3	  and	  571	  
demethylated	   into	   DMA	   and	   MMA	   by	   cytochrome	   P450s	   (CYP)	   in	   the	   liver	   during	   first-­‐pass	  572	  
metabolism.	   Circulating	   TMAO	   can	   reach	   other	   cell	   types,	   such	   as	   arterial	   epithelial	   cells	   and	  573	  
macrophages,	   leading	   to	   atherosclerosis-­‐associated	   inflammation.	   PC,	   synthesized	   from	   choline	  574	  
through	  the	  Kennedy	  (CDP-­‐choline)	  pathway,	   is	  essential	   for	  exporting	  fatty	  acids	   from	  the	   liver	  to	  575	  
other	  storage	  tissues;	  reduced	  choline	  bioavailability	  leads	  to	  lower	  levels	  of	  PC	  being	  formed	  and	  to	  576	  
NAFLD.	   PEMT	   converts	   phosphatidylethanolamine	   (PE)	   into	   PC,	   using	   S-­‐adenosylmethionine	   as	   a	  577	  
methyl	   donor,	   and	  a	  polymorphism	   in	  PEMT	   has	  been	  associated	  with	   a	  higher	   risk	  of	   developing	  578	  
NAFLD.	   When	   there	   is	   sufficient	   choline	   in	   the	   diet,	   the	   Kennedy	   pathway	   is	   responsible	   for	  579	  
maintaining	   PC	   synthesis,	   with	   the	   PEMT	   pathway	   contributing	   ~30	   %	   of	   the	   hepatic	   PC.	   When	  580	  
choline	  is	  at	  low	  levels	  in	  the	  diet,	  the	  PEMT	  pathway	  is	  essential	  for	  maintaining	  the	  supply	  of	  PC	  in	  581	  
the	  liver.	  Adapted	  from	  [41,57,63**,	  64**,65**].	  582	  
	  583	  
